BCRX
BioCryst to Report First Quarter 2026 Financial Results on May 6
Article Summary
HOLD- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) announced that Biocryst Pharmaceuticals will report its first quarter 2026 financial results on Wednesday, May 6, 2026, with management hosting a conference call and webcast at 8:30 a.m.
- ET that day to discuss financial results and provide a corporate update.
- The company is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases driven by its deep commitment to improving the lives of people living with these conditions.
- BioCryst has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 94.1% | 25% | 100.0 ptsExceptional (94.1%) - Hypergrowth |
| EPS Growth Next 5Y ? | -27.6% | 25% | 0.0 ptsNegative (-27.6%) - Declining expectations |
| Target Price Upside ? | 120.6% | 20% | 100.0 ptsMassive Upside (120.6%) - Target: $21.40 vs Current: $9.70 |
| Gross Margin % ? | 97.7% | 15% | 100.0 ptsExceptional (97.7%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -14.2% | 15% | 40.0 ptsMild Pullback (-14.2%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About BCRX
- BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
- The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
- It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
- The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S.
- Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.
- BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.